Purpose: The repositioning of previously approved drugs is occupying the researchers’ plans. Baclofen (Bac) was our candidate for its established neuroprotective capacity, with a proposal of efficient drug delivery as non-ionic surfactant-based nanovesicles (NISNV) formulae against mild repetitive traumatic brain injury (mRTBI) in rats, thus reducing the number of orally or injected medications, especially in severely comatose patients or pediatrics. Methods: A (23 ) factorial design was implemented for confining Bac-loaded NISNV formulae, where a bunch of variables were inspected. An in-vivo experiment was done to test the prepared formula’s efficacy transdermally. The following parameters were measured: brain expression of gamma amino butyric acid B (GABAB), protein kinase C- α (PKC-α), focal adhesion kinase (FAK), TNF-α and nuclear factor kappa B (NF-κB) p65, malondialdehyde (MDA), superoxide dismutase (SOD), and histopathology. Results: The particle size (PS) and entrapment efficiency percent (EE%) speckled from 60.40±0.28% to 88.02±0.01% for the former and 174.64±0.93 to 1174.50±3.54 nm for the latter. In vitro release% after 8 hours ranged from 63.25±5.47% to 84.79±3.75%. The optimized formula (F4) illustrated desirability=1, with 630.09±3.53 µg/cm2 of Bac permeated over 8 hours, which equates to 100% of Bac. Bac post-trauma treatment restored brain expression of GABAB and PKC-α, while decreasing FAK. Besides enhancing the histological findings, the anti-inflammatory effect was clear by decreasing TNF-α and NF-κB p65. Consequently, significant antioxidant sequelae were revealed herein by diminishing MDA levels and restoring SOD activity. Conclusion: Transdermal delivery of Bac-loaded niosomes confirmed neuroprotection and succeeded in surpassing skin-to-brain barriers, which makes it a promising therapeutic option for repeated traumas.
The widespread heavy metal, potassium dichromate (PDC), presents an actual threat because of its high toxicity to all body organs. This research was designed to study the possible cytotoxicity and genotoxicity exerted by PDC on Alzheimer’s disease (AD) and the prospect negative effect on AD induced in rats. The current research was performed on forty male rats, classified similarly into 4 sets: normal control, AD control was done by intraperitoneal injection of lipopolysaccharide (LPS) at a dose 250 µg/kg body weight for 7 days, AD intraperitoneally injected once by PDC 10 mg/kg body weight, and PDC-intoxicated rats (same as the third group). The forth group served to compare the effect of PDC alone. Twenty-four hours after the PDC injection, rats were sacrificed to collect their brain hippocampi (CA3 region) to study its histopathological structure, acetylcholinesterase (AChE) gene expression by RT-PCR, malondialdehyde (MDA) content and catalase (CAT) activity spectrophotometrically. Additionally, cells of the bone marrow were harvested from the rat femoral bone to undergo in-vivo micronucleus (MN) assay. The outcomes entailed that AD rats with PDC significantly altered the hippocampal histology, vanished neuronal survival count, increased AChE gene expression, MDA content and CAT activity in AD rats more than normal and PDC-only rats. Furthermore, PDC significantly elevated frequency of MN in AD rats’ bone marrow cells. In conclusion, the study results evidenced that PDC exerted a tremendous harm to the AD case, evident by all previously mentioned outcomes.